Loading clinical trials...
Loading clinical trials...
A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer
Conditions
Interventions
bicalutamide
estramustine phosphate sodium
+6 more
Locations
54
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
Foundation for Cancer Research and Education
Phoenix, Arizona, United States
Mount Diablo Medical Center
Concord, California, United States
Sutter Health Western Division Cancer Research Group
Greenbrae, California, United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, United States
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, United States
Start Date
January 1, 2000
Primary Completion Date
April 1, 2010
Completion Date
November 1, 2013
Last Updated
October 22, 2020
NCT06594926
NCT07177937
NCT06926283
NCT06844383
NCT05919264
NCT07004582
Lead Sponsor
Radiation Therapy Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions